Leflunomide Relonchem

Leflunomide, the active ingredient in Leflunomide Relonchem, is an immunomodulatory agent presented as an oral formulation for systemic oral use. It is employed to effectively manage rheumatoid arthritis and psoriatic arthritis in adult patients requiring disease‑modifying therapy in clinical practice.

GNH USA supplies Leflunomide Relonchem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides quality‑assured products, follows Good Manufacturing Practice, and offers reliable logistics to meet the needs of healthcare providers across multiple regions.

Leflunomide is a disease‑modifying antirheumatic drug (DMARD) that interferes with immune cell proliferation, making it effective for chronic inflammatory joint disorders.

Rheumatoid arthritis: diminishes joint swelling and pain, slows radiographic progression, and improves physical function in adults with moderate to severe disease. Psoriatic arthritis: reduces joint inflammation, limits skin lesion exacerbation, and helps maintain mobility in patients with active psoriatic arthritis. Early rheumatoid arthritis: contributes to remission rates when used in combination with other disease‑modifying agents, supporting early disease control.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of sickness or urge to vomit. - Rash: skin redness or itching. - Elevated liver enzymes: increased ALT/AST levels.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure requiring monitoring. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Bone marrow suppression: pancytopenia or anemia.

Before prescribing Leflunomide, clinicians should consider several safety measures. - Liver function monitoring: check ALT/AST before starting and periodically during therapy. - Blood pressure monitoring: measure regularly to detect hypertension. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Infection risk assessment: evaluate for active infections before initiating. - Drug discontinuation before surgery: stop therapy as advised to reduce wound‑healing complications. - Store at ambient temperature: keep in original packaging, protect from moisture.

Leflunomide interacts with several medicines; some combinations should be avoided while others require close observation.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, may raise INR. - Methotrexate: additive hepatotoxicity and bone marrow suppression. - Cholestyramine: reduces leflunomide absorption, decreasing efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance liver enzyme elevations. - Statins: increased risk of myopathy. - Oral contraceptives: may reduce contraceptive effectiveness.